The results of three clinical trials in the treatment of new Crown patients with ruixway were announced on the 29th, and the results of various studies were different. The National Institutes of Health announced the preliminary results of a clinical trial on the 29th. This randomized, controlled clinical trial began in February 21 with 1063 patients from 68 sites in the United States, Europe and Asia. These patients who participated in clinical trials were seriously ill and had symptoms of pulmonary infection.
Preliminary trial results showed that the recovery time of patients treated with redseway was 31% faster than that of patients in the control group treated with placebo. Judging from the median recovery time, the former is 11 days and the latter is 15 days. The mortality rate was 8% in patients treated with rethevir and 11.6% in the control group.
The National Institutes of Health said the clinical trial was evaluated by an independent data and safety monitoring committee. The committee shared the results of the interim analysis on the 27th, and found that the patient’s recovery time was better than the placebo.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the 29th that the clinical trial data showed that radsiwei had a significant effect on reducing the recovery time of patients.
Ruiqiwei is an antiviral drug developed by Gilead technology company in the United States. It was originally planned to be used to treat Ebola hemorrhagic fever and Middle East respiratory syndrome and other diseases. It has not been approved for listing in any country in the world.
Gilead technologies also announced the results of another Phase III clinical trial led by it on the 29th. The patients in this clinical trial were divided into two groups and were treated with rethewei for 5 and 10 days respectively.
The results showed that 14th of the patients who received 5-day treatment with redexivir recovered at 64.5% day after starting treatment, and 53.8% of the patients who received 10-day treatment with redexivir recovered.
Gilead said the trial was aimed at evaluating whether treatment with rethevir for 5 days could achieve the same effect as 10 days, as well as evaluating adverse drug reactions and other clinical indicators. The company also said it was conducting other clinical trials on redseway.
Philip Bass, a professor at the University of Nottingham in the United Kingdom, commented that the aforementioned clinical trial did not set up a control group that did not use redseway, and it was not easy to draw conclusions on effectiveness and other aspects.
The British Medical Journal “Lancet” published online on the 29th the results of a ruixway clinical trial conducted in China. According to the paper, 237 adult critically ill patients participated in this randomized, double-blind, controlled trial.
The results showed that the median clinical improvement time was 21 days in the redseway group and 23 days in the placebo group. The researchers believe that although there are some differences, but did not reach a statistically significant level. The researchers say a larger study is needed to test the effects of redseway.
(Original title: results of three clinical trials of ruixway, reporter Tan Jingjing)